<DOC>
	<DOCNO>NCT00673478</DOCNO>
	<brief_summary>The primary objective study characterize pharmacokinetics ( i.e . systemic exposure tiotropium salmeterol ) tiotropium qd + salmeterol qd bid versus tiotropium qd salmeterol bid follow 4-week treatment period patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Tiotropium Salmeterol PK Study COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>COPD patient &gt; = 40 year old moderate severe COPD current exsmokers smoke history least 10 packyears 1 . Recent history myocardial infarction , lifethreatening cardiac arrhythmia hospitalisation cardiac failure 2 . History asthma 3 . Malignancy require treatment within past 5 year 4 . Lifethreatening pulmonary obstruction , cystic fibrosis clinically evident bronchiectasis 5 . Known active tuberculosis 6 . Pregnant nusing woman 7 . Known hypersensitivity component study medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>